The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Response-adapted therapy with copanlisib and rituximab for previously untreated FL
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, discusses a Phase II study (NCT03789240) assessing the efficacy of response-adapted therapy with copanlisib and rituximab for patients with previously untreated follicular lymphoma (FL). Nearly all patients were responsive to the PI3K inhibitor copanlisib, and the combination of copanlisib with rituximab achieved a complete response (CR) rate of 60% after six cycles. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
